Meiragtx Holdings (MGTX) AI Stock Analysis

• Market Cap: $660.03M
• Dividend Yield: N/A
• Average Volume (3M): 516.00K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.43
• Revenue Growth: 96.83%
• EPS Growth: -61.92%
• Country: US
• Employees: 375
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.62
• Shares Outstanding: 80,490,890
• 10 Day Avg. Volume: 608,858
• 30 Day Avg. Volume: 516,004
• PEG Ratio: -0.07
• Price to Book (P/B): 6.27
• Price to Sales (P/S): 12.78
• P/FCF Ratio: -3.89
• Enterprise Value/Market Cap: 1.12
• Enterprise Value/Revenue: 26.97
• Enterprise Value/Gross Profit: 65.76
• Enterprise Value/Ebitda: -5.15
• 1Y Price Target: $22.50
• Price Target Upside: 174.39% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 6
• EPS Forecast (FY): -1.61
• Revenue Forecast (FY): $27.48M

• Rating: 44 Neutral
• Price Target: $8.00 ▼(-2.44% Downside)

Meiragtx Holdings' overall stock score is primarily impacted by its poor financial performance, which is the most significant factor. Technical analysis provides mixed signals, while valuation metrics indicate high risk due to negative profitability. The lack of earnings call and corporate events data means these components do not influence the score.

Positive Factors

Strategic Collaboration

The collaboration with Eli Lilly provides MeiraGTx with significant resources and expertise, enhancing its ability to develop and commercialize gene therapies, particularly in ophthalmology, which can drive long-term growth and strengthen its market position.

Cash Position

The substantial cash inflow from strategic collaborations ensures MeiraGTx can fund operations and capital expenditures into 2027, reducing financial risk and supporting ongoing R&D efforts.

Pipeline Progress

Advancements in clinical trials for key therapies indicate potential for future product approvals, which could lead to significant revenue streams and strengthen MeiraGTx's market position in gene therapy.

Negative Factors

Declining Revenue

A significant decline in revenue highlights challenges in maintaining consistent income streams, which may impact the company's ability to fund R&D and operations without external financing.

High Leverage

High leverage indicates financial instability, limiting MeiraGTx's flexibility to invest in growth opportunities and increasing vulnerability to economic downturns.

Negative Profit Margins

Sustained negative profit margins reflect challenges in achieving profitability, which could hinder long-term sustainability and necessitate cost management improvements.

Meiragtx Holdings Business Overview & Revenue Model

Company Description

MeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited blindness, as well as Xerostomia following radiation treatment for head and neck cancers; degenerative diseases; neurodegenerative diseases, such as amyotrophic lateral sclerosis; and Parkinson's diseases. Its programs in clinical development include Phase 1/2 clinical stage programs in Achromatopsia, X-Linked Retinitis Pigmentosa, RPE65-deficiency, and radiation-induced Xerostomia, as well as Parkinson's program. The company also focuses on initiating a clinical program in xerostomia related to Sjogren's syndrome and have preclinical programs in neurodegenerative diseases. It has a research collaboration agreement with Janssen Pharmaceuticals, Inc. to develop regulatable gene therapy treatment using the company's proprietary riboswitch technology. MeiraGTx Holdings plc was incorporated in 2015 and is based in New York, New York.

How the Company Makes Money

Meiragtx Holdings generates revenue primarily through the development and commercialization of its gene therapy products. The company earns money by conducting clinical trials and subsequently bringing successful therapies to market, which can lead to significant sales revenue from healthcare providers and patients. Additionally, MGTX may enter into strategic partnerships and collaborations with larger pharmaceutical companies for co-development and marketing of its therapies, receiving milestone payments and royalties based on sales performance. Grants and funding from research institutions or government bodies can also contribute to its revenue, especially in the early stages of product development.

Meiragtx Holdings Financial Statement Overview

Summary

Meiragtx Holdings is facing significant financial challenges, including declining revenues, negative profit margins, high leverage, and cash flow difficulties. The income statement, balance sheet, and cash flow scores are all low, reflecting the need for substantial improvement in revenue generation, cost management, and financial stability.

Income Statement

Meiragtx Holdings has faced significant challenges in its income statement, with declining revenue and negative profit margins. The TTM data shows a revenue decline of 27.69%, and the net profit margin is deeply negative at -415.39%. The company is struggling to achieve profitability, as indicated by negative EBIT and EBITDA margins. These factors contribute to a low score, reflecting the need for substantial improvement in revenue generation and cost management.

Balance Sheet

The balance sheet reveals a concerning financial position with a negative stockholders' equity and a high debt-to-equity ratio of 27.19 in the TTM period. This indicates significant leverage and financial instability. The return on equity is also negative, highlighting the company's inability to generate returns for shareholders. The equity ratio is not calculable due to negative equity, further emphasizing financial distress.

Cash Flow

Cash flow analysis shows negative operating and free cash flows, with a slight improvement in free cash flow to net income ratio at 1.04 in the TTM period. However, the operating cash flow to net income ratio is negative, indicating cash flow challenges. The company needs to enhance its cash generation capabilities to support operations and reduce reliance on external financing.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	27.42M	33.28M	14.02M	15.92M	37.70M	15.56M
Gross Profit	11.24M	9.49M	14.02M	15.92M	37.70M	15.56M
EBITDA	-143.50M	-121.69M	-57.05M	-116.07M	-71.40M	-53.68M
Net Income	-168.69M	-147.79M	-84.03M	-129.62M	-79.56M	-57.99M
Balance Sheet
Total Assets	189.47M	269.75M	326.74M	318.24M	320.16M	363.70M
Cash, Cash Equivalents and Short-Term Investments	14.84M	103.66M	129.57M	115.52M	137.70M	209.52M
Total Debt	88.06M	84.80M	89.26M	92.25M	23.73M	22.25M
Total Liabilities	230.03M	201.92M	188.57M	200.50M	134.76M	125.14M
Stockholders Equity	-40.56M	67.83M	138.18M	117.74M	185.40M	238.56M
Cash Flow
Free Cash Flow	-121.04M	-109.45M	-125.54M	-118.06M	-65.75M	-100.99M
Operating Cash Flow	-116.27M	-104.50M	-105.36M	-73.10M	-10.53M	-63.97M
Investing Cash Flow	-4.24M	23.48M	34.03M	-44.96M	-61.72M	-37.02M
Financing Cash Flow	11.19M	54.53M	84.02M	95.20M	1.71M	82.73M

Meiragtx Holdings Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 8.20
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For MGTX, the sentiment is Positive. The current price of 8.2 is below the 20-day moving average (MA) of 8.23, below the 50-day MA of 8.30, and above the 200-day MA of 7.24, indicating a neutral trend. The MACD of -0.20 indicates Positive momentum. The RSI at 51.15 is Neutral, neither overbought nor oversold. The STOCH value of 34.32 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for MGTX.

Meiragtx Holdings Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
TSHA	58 Neutral	$1.26B	―	-64.93%	―	-36.36%	-945.72%
FDMT	53 Neutral	$610.20M	―	-45.38%	―	―	―
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
TERN	45 Neutral	$2.64B	―	-29.12%	―	―	12.45%
MGTX	44 Neutral	$660.03M	―	-611.42%	―	96.83%	-61.92%
OPT	39 Underperform	$477.76M	-3.01	―	―	-80.09%	60.14%
ERAS	34 Underperform	$888.02M	―	-32.00%	―	―	45.66%

Meiragtx Holdings Corporate Events

MeiraGTx Reports Q3 2025 Results and Strategic Advances

MeiraGTx Holdings plc is a clinical-stage genetic medicines company specializing in the development of gene therapies for both rare and common diseases, with a focus on ophthalmology, Parkinson’s disease, and radiation-induced xerostomia. The company has recently announced its third-quarter 2025 financial and operational results, highlighting significant strategic collaborations and advancements in their clinical programs.

MeiraGTx and Eli Lilly Collaborate on Genetic Medicines

On November 7, 2025, MeiraGTx entered into a strategic collaboration with Eli Lilly to develop and commercialize genetic medicines in ophthalmology. The agreement grants Lilly exclusive rights to MeiraGTx’s AAV-AIPL1 program, which has shown unprecedented success in restoring vision in children with Leber congenital amaurosis 4. MeiraGTx will receive a $75 million upfront payment and is eligible for over $400 million in milestone payments, along with tiered royalties. This collaboration highlights MeiraGTx’s leadership in genetic medicine and Lilly’s interest in expanding its ophthalmology portfolio, potentially bringing transformative treatments to patients worldwide.

The most recent analyst rating on (MGTX) stock is a Hold with a $9.50 price target. To see the full list of analyst forecasts on Meiragtx Holdings stock, see the MGTX Stock Forecast page.

MeiraGTx’s Gene Therapy Study for Xerostomia: A Promising Update

Study Overview: MeiraGTx Holdings is conducting a study titled Long-term Follow-up of AAV2-hAQP1 Gene Therapy in Participants With Radiation-Induced Late Xerostomia. The study aims to evaluate the long-term safety and efficacy of a gene therapy treatment for adults suffering from Grade 2 or Grade 3 xerostomia caused by radiotherapy for cancers of the upper aerodigestive tract. This research is significant as it could provide a lasting solution for patients experiencing severe dry mouth due to cancer treatments.

MeiraGTx’s Gene Therapy Trial: A Potential Game-Changer for Radiation-Induced Xerostomia

MeiraGTx Holdings is conducting a clinical study titled ‘A Randomized, Double-Blind, Placebo-Controlled Study to Determine the Efficacy and Safety of AAV2-hAQP1 Gene Therapy in Participants With Radiation-Induced Late Xerostomia.’ The study aims to evaluate the effectiveness and safety of the AAV2-hAQP1 gene therapy in adults suffering from late-stage xerostomia caused by radiation therapy, a condition that significantly impacts quality of life.

MeiraGTx Reports Progress in Genetic Medicines Development

MeiraGTx Holdings plc is a clinical-stage genetic medicines company focused on developing innovative therapies for inherited and common diseases, with a strong emphasis on end-to-end in-house manufacturing capabilities. In its latest earnings report, MeiraGTx highlighted significant regulatory progress and strategic collaborations, notably gaining FDA alignment for its Phase 2 study in radiation-induced xerostomia and receiving RMAT designation for its Parkinson’s disease treatment. Key financial metrics showed a net loss reduction compared to the previous year, with service revenue increasing due to enhanced collaboration with Johnson & Johnson. The company also announced a strategic partnership with Hologen to advance its Parkinson’s disease program and other CNS therapies, supported by a $200 million investment. Looking ahead, MeiraGTx remains focused on advancing its late-stage clinical programs and leveraging its proprietary technologies to address unmet medical needs, with a robust financial position to support its strategic initiatives into 2027.